Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: A meta-analysis of randomized clinical trials

Diabetic Medicine

Volumn 27, Issue 3, 2010, Pages 309-317

  DeFronzo, R A ^a   Stonehouse, A H ^b   Han, J ^b   Wintle, M E ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Clinical studies; Diabetes; Glycated haemoglobin; Therapy

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN DERIVATIVE; MEGLITINIDE; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESEARCH; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW; BLOOD; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77949416255     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02941.x     Document Type: Article

References (75)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
7. The American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: S16.
8. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowe-ring efficacy: a meta-regression analysis. Diabetes Care 2006; 29: 2137-2139.
9. 1c: a meta-analysis of published randomized clinical trials. Curr Med Res Opin 2006; 22: 2267-2278.
10. Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control? Curr Med Res Opin 2003; 19: 192-199.
11. Shojania KG, Ranji SR, McDonald KM, Grimshaw JM, Sundaram V, Rushakoff RJ et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. J Am Med Assoc 2006; 296: 427-440.
12. Food and Drug Administration. Draft guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. 2008. Available at http://www.fda.gov/cder/guidance/7630dft.pdf Last accessed 16 October 2008.
13. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. 2002. Available at http://www.emea.europa.eu/pdfs/human/ewp/108000en.pdf Last accessed 16 October 2008.
14. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF et al. Improving the quality of reports of meta-analyses of rando-mised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896-1900.
15. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-932.
16. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991; 14: 342-344.
17. 1c. Diabetes Care 2003; 26: 881-885.
18. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
19. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR. One-year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 1994; 20: 394-400.
20. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide plus acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-451.
21. Halimi S, Le Berre MA, Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56.
22. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet Med 1993; 10: 134-138.
23. Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA. Long-term effectiveness of a new a-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated Type 2 diabetes mellitus. Diabet Med 1998; 15: 657-660.
24. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-273.
25. Van Gaal L, Maislos M, Schernthaner G, Rybka J, Segal P. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab 2001; 3: 326-331.
26. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182-188.
27. Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005; 27: 1548-1561.
28. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
29. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. The Metformin Trial Group. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005; 22: 634-640.
30. Hermann LS, Kalén J, Katzman P, Lager I, Nilsson A, Norrhamn O et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 2001; 3: 428-434.
31. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE study. Curr Med Res Opin 2005; 21: 2029-2035.
32. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-1611.
33. Dailey GE, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-229.
34. Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, Montes-Villarreal J, Berry RA, Warsi G et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-134.
35. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
36. Majima T, Komatsu Y, Doi K, Shigemoto M, Takagi C, Fukao A et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J 2006; 53: 325-330.
37. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-523.
38. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004; 27: 2585-2589.
39. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-1645.
40. Perriello G, Pampanelli S, Di Pietro C, Brunetti P, Italian Pioglitazone Study Group. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med 2006; 23: 246-252.
41. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
42. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A et al; Rosiglitazone Clinical Trials Study Group. Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-315.
43. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J et al; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232.
44. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
45. Scherbaum WA, Göke B, German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-595.
46. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076.
47. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005; 54: 24-32.
48. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22: 751-759.
49. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med 2005; 22: 980-985.
50. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 1535-1547.
51. Tessier D, Maheux P, Khalil A, Fülöp T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999; 48: 897-903.
52. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25: 472-484.
53. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003; 60: 161-169.
54. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-1665.
55. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57.
56. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A, Scandinavian Repaglinide Group. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multi-centre study. Diabet Med 2001; 18: 395-401.
57. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-467.
58. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
59. Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.
60. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
61. Pan CY, Sinnassamy P, Chung KD, Kim KW, LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 2007; 76: 111-118.
62. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
63. Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-1136.
64. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M, Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006; 29: 1282-1287.
65. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M, Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006; 29: 1818-1825.
66. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS et al; Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362.
67. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD et al; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
68. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
69. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
70. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26: 784-790.
71. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51-61.
72. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
73. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE et al; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
74. Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during 1-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006; 55: A29.
75. Fonseca V, Dejager S, Albrecht D, Shirt L, Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006; 55: A111.